In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin

British Journal of Cancer

Volumn 75, Issue 6, 1997, Pages 869-877

  Jensen, P B ^a   Holm, B ^a   Sorensen, M ^a   Christensen, I J ^a   Sehested, M ^b  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Clonogenic assay; Collateral sensitivity; Multidrug resistance; New drug combinations; Resistance to alkylating agents and topoisomerase I poisons

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; ANTINEOPLASTIC METAL COMPLEX; BLEOMYCIN; CAMPTOTHECIN DERIVATIVE; CARMUSTINE; CHLORMETHINE DERIVATIVE; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; PACLITAXEL; TENIPOSIDE; TOPOTECAN;

ARTICLE; CANCER CELL CULTURE; CLONOGENIC ASSAY; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0031039517     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.154     Document Type: Article

References (39)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540
2. Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell king cancer: a phase II study. J Clin Oncol 12: 1821-1826
3. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
4. Belani CP, Aisner J, Hiponia D and Engstrom C (1995) Paclitaxel and Carboplatin with and without Filgrastrim Support in Patients with Metastatic Non-Small-Cell-Lung Cancer. Semin Oncol 22: (suppl. 9): 7-12
5. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC and Schested M (1995) Sequential co-expression of the multidrug resistance genes, MRP and mdr1 and their products in VP-16 (etoposide) selected H69 small cell lung cancer cells. Cancer Res 55: 459-462
6. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH and Minna JD (1985) Establishment and identification of small cell lung cancer cell lines having classic and variant leatures Cancer Res 45: 2913-2923
7. Chen AY, YU C. Potmesil M, Wall ME, Wani MC and Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039-6044
8. Cormier Y, Eisenhaueer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P and Wong D (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 5: 283-285
9. De Leij L, Postmus PE, Buys CHCM, Elema JD, Ramaekers F, Poppema S, Brouwer M, Van der Veen AY, Mesander G and The Th (1985) Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 45: 6024-6033
10. Dolan ME, Muschel RC and Pegg AE (1990) Depletion of mammalian O-alkylguanine-DNA alkyltransferase activity by O-benzylguanine provides a means to evaluale the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87: 5368-5372
11. Eder JP, Chan V T-W, NG S-W, Rizvi NA, Zacharoulis S, Teicher BA and Schnipper LE (1995) DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 55: 6109-6116
12. Gelmon K (1995) Biweekly Paclitaxel in the Treatment of Patients with Metastatic Breast Cancer. Semin Oncol 22: (suppl. 12) 117-122
13. Giaccone G, Gazdar AF, Beck H, Zunino F and Capranico G (1992) Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674
14. Hansen HH (1992) Management of small-cell cancer of the lung. Lancet 339: 846-849
15. Hendriks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SKANDF 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
16. Jensen PB, Vindeløv L, Roed H, Demant EJF, Sehested M, Skovsgaard T and Hansen HH (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 60: 838-844
17. Jensen PB, Roed H, Sehested M, Demant EJF, Vindeløv L, Christensen IJ and Hansen HH (1992) Doxorubicin sensitivity pattern in a panel of small cell lung cancer cell lines: correlation to etoposide and vincristine and inverse correlation to carmustine sensitivity. Cancer Chemother Pharmacol 31: 46-52
18. Jensen PB, Christensen IJ, Sehested M, Hansen HH and Vindeløv L (1993a) Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 67: 311-320
19. Jensen PB, Sørensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E and Hansen HH (1993b) Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025-2035
20. Keating MJ, Estey E and Kantarjian H (1993) Acute Leukemia. In Cancer Principles and Practice of Oncology 4th ed, De Vita VT, Hellman S and Rosenberg SA (eds), pp. 1938-1964. Lippincott: Philadelphia
21. Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, Bolund L and Westergaard O (1988) Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 263: 3912-3916
22. Koutsoukos AD, Rubinstein LV, Faraggi D, Simon RM, Kalyandrug S, Weinstein JN, Kohn KW and Paull KD (1994) Discrimination techniques applied to the NCI in vitro anti-tumour drug screen - predicting biochemical mechanism of action. Statist Med 13: 719-730
23. Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J and Riou G (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase. Biochem Pharmacol 41: 1967-1979
24. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
25. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y and Saijo N (1990) Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 26: 313-317
26. Oguro M, Seki Y, Okada K and Andoh T (1990) Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother 44: 209-216
27. Roed H, Christensen IJ, Vindeløv L, Spang-Thomsen M and Hansen HH (1987) Interexperiment variation and dependence on culture conditions in assaying chemosensitivity of human small cell lung cancer lines. Eur J Cancer Clin Oncol 23: 177-186
28. Schabel FM JR, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr and Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905-922
29. Sehested M, Friche E, Jensen PB and Demant EJF (1992) Relationship of VP-16 to the classical multidrug resistance (MDR) phenotype. Cancer Res 52: 2874-2879
30. Sorensen M, Sehested M and Jensen PB (1995) Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72: 399-404
31. Sugimoto Y, Tsukahara S, Oh Hara T, Isoe T and Tsuruo T (1990a) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930
32. Sugimoto Y, Tsukahara S, OH Hara T, Liu LF and Tsuruo T (1990b) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962-7965
33. Tan KB, Mattern MR, Boyce RA and Schein PS (1987) Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells. Proc Natl Acad Sci USA 84: 7668-7671
34. Tan KB, Mattern MR, Eng W-K, McCabe FL and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735
35. Tanizawa A and Pommier Y (1992) Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1848-1854
36. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27: 502-522
37. Tsai C, Ihde DC, Kadoyama C, Venzon D and Gazdar AF (1990) Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. Eur J Cancer 26: 1148-1152
38. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJ and Paull KD (1992) Neural computing in cancer drug development: predicting mechanism of action. Science 258: 447-451
39. Vindeløn L and Christensen IJ (1990) A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine flow cytometric DNA analysis. Cytometry 11: 753-770